Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10010802 | 0.86 | NPC1 (0.36) | NPC1TSHRCYP1A2CHRM2CHRM4 | |
| SCHEMBL4675815 | 0.85 | NPC1 (0.35) | NPC1TSHRCYP1A2CHRM2CHRM4 | |
| SCHEMBL4675969 | 0.81 | L3MBTL1 (0.34) | NPC1TSHR | |
| SCHEMBL10010316 | 0.81 | ACHE (0.37) | NPC1TSHR | |
| SCHEMBL4675964 | 0.80 | ZDHHC20 (0.33) | NPC1 | |
| SCHEMBL10010758 | 0.78 | GAA (0.39) | GAANPC1CYP1A2CHRM2CHRM4 | |
| SCHEMBL2478567 | 0.77 | NPC1 (0.41) | GAANPC1TSHRCYP1A2CHRM2 | |
| SCHEMBL27657800 | 0.77 | NPC1 (0.41) | NPC1TSHRCYP1A2CHRM2CHRM4 | |
| SCHEMBL7065716 | 0.77 | NPC1 (0.35) | NPC1TSHRCYP1A2CHRM2CHRM4 | |
| SCHEMBL10012425 | 0.76 | TSHR (0.32) | NPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9130244-B2 | Nonaqueous electrolyte solution and electrochemical element using same | UBE INDUSTRIES, LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| EP-2908376-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2015-08-19 | — | — | EP | disclosed |
| EP-2479831-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120171581-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES, LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-1095935-B1 | 6-Hydroxy-5,6-dihydrouracils as herbicides | SUMITOMO CHEMICAL CO (JP) | 2008-12-17 | — | — | EP | disclosed |
| EP-1101761-B1 | Process for producing 3-phenyluracil compounds | SUMITOMO CHEMICAL CO (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20030216258-A1 | Condensed heterocylic compounds and herbicides containing them as active ingredients | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-11-20 | — | — | US | disclosed |
| US-6586368-B1 | Benzofuran derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-01 | — | — | US | disclosed |
| US-6410484-B1 | ACTIVE MATERIAL; CONTROLLING WEEDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6339155-B1 | Process for producing 3-phenyluracil compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-15 | — | — | US | disclosed |
| EP-1101761-A2 | Process for producing 3-phenyluracil compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-05-23 | — | — | EP | disclosed |
| EP-1095935-A1 | 6-Hydroxy-5,6-dihydrouracils as herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216258-A1 | Condensed heterocylic compounds and herbicides containing them as active ingredients | CBR3, CBR1, HAAO | GAA 3021/4885NPC1 4434/4885TSHR 1858/4885 |
| US-20120171581-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | SLC8A1, OR10J3, SLC8B1 | GAA 4655/4885NPC1 2731/4885TSHR 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.